These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 28812060)
21. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation. Beliakova-Bethell N; Mukim A; White CH; Deshmukh S; Abewe H; Richman DD; Spina CA J Biol Chem; 2019 Apr; 294(14):5576-5589. PubMed ID: 30745362 [TBL] [Abstract][Full Text] [Related]
22. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Li D; Marchenko ND; Moll UM Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290 [TBL] [Abstract][Full Text] [Related]
23. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells. You BR; Han BR; Park WH Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148 [TBL] [Abstract][Full Text] [Related]
24. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Blumenschein GR; Kies MS; Papadimitrakopoulou VA; Lu C; Kumar AJ; Ricker JL; Chiao JH; Chen C; Frankel SR Invest New Drugs; 2008 Feb; 26(1):81-7. PubMed ID: 17960324 [TBL] [Abstract][Full Text] [Related]
25. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). Hendricks JA; Keliher EJ; Marinelli B; Reiner T; Weissleder R; Mazitschek R J Med Chem; 2011 Aug; 54(15):5576-82. PubMed ID: 21721525 [TBL] [Abstract][Full Text] [Related]
26. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Negmeldin AT; Knoff JR; Pflum MKH Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330 [TBL] [Abstract][Full Text] [Related]
27. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck. Chikamatsu K; Ishii H; Murata T; Sakakura K; Shino M; Toyoda M; Takahashi K; Masuyama K Cancer Sci; 2013 Nov; 104(11):1468-75. PubMed ID: 23992541 [TBL] [Abstract][Full Text] [Related]
29. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo. Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428 [TBL] [Abstract][Full Text] [Related]
30. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics. Zhou X; Yang XY; Popescu NC Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346 [TBL] [Abstract][Full Text] [Related]
31. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives. Pu J; Liu T; Wang X; Sharma A; Schmidt-Wolf IGH; Jiang L; Hou J Exp Hematol Oncol; 2024 Apr; 13(1):45. PubMed ID: 38654286 [TBL] [Abstract][Full Text] [Related]
32. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication. Saha B; Parks RJ J Virol; 2019 Jun; 93(12):. PubMed ID: 30944181 [TBL] [Abstract][Full Text] [Related]
33. Influence of natural and synthetic histone deacetylase inhibitors on chromatin. Licciardi PV; Kwa FA; Ververis K; Di Costanzo N; Balcerczyk A; Tang ML; El-Osta A; Karagiannis TC Antioxid Redox Signal; 2012 Jul; 17(2):340-54. PubMed ID: 22229817 [TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents. Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876 [TBL] [Abstract][Full Text] [Related]
35. Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats. Chakrabarty R; Tran H; Boulay I; Moran T; Parenteau A; Tavcar R; Bigras M; Hagerman A; Serl S; Thompson B; Coffey M Invest New Drugs; 2013 Dec; 31(6):1476-86. PubMed ID: 24121993 [TBL] [Abstract][Full Text] [Related]
36. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid. Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198 [TBL] [Abstract][Full Text] [Related]